Home › Compare › CZGZF vs ABBV
CZGZF yields 1.57% · ABBV yields 3.09%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, CZGZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CZGZF + ABBV for your $10,000?
Colt CZ Group SE, together with its subsidiaries, engages in the production, purchase, and sale of firearms, ammunition products, and tactical accessories in the Czech Republic, the United States, rest of Europe, Africa, Asia, and internationally. Its firearms include pistols, revolvers, rifles, submachine guns, grenade launchers, machine guns, sniper rifles, shotguns, and centrefire rifles; and components for firearms comprising sights, optical mounting solutions, triggers, stocks, grips, and spare parts. The company also offers tactical and ballistic equipment, such as ballistic vests, helmets and other protection products, combat uniforms, and backpacks, as well as firearms accessories consisting of handgun holsters, magazine pouches, and slings. In addition, it is also involved in the lease of real estate properties; and trade of military materials. The company markets and sells its products under the Colt, CZ (Ceská zbrojovka), CZ-USA, Colt Canada, Dan Wesson, Brno Rifles, and 4M Systems brands. It sells its products for armed forces, military and law enforcement, personal defense, hunting, sport shooting, and other civilian uses. The company was formerly known as CZG - Ceská zbrojovka Group SE and changed its name to Colt CZ Group SE in April 2022. The company was founded in 1936 and is headquartered in Prague, the Czech Republic. Colt CZ Group SE is a subsidiary of Ceska Zbrojovka Partners SE.
Full CZGZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.